Vise Technologies Inc. Has $2.54 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Vise Technologies Inc. raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 34.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,870 shares of the biopharmaceutical company's stock after purchasing an additional 11,615 shares during the period. Vise Technologies Inc.'s holdings in Bristol-Myers Squibb were worth $2,538,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Transce3nd LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $34,000. Tacita Capital Inc acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $39,000. Finally, M Holdings Securities Inc. acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $39,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BMY. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group cut their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $46.99 on Friday. The stock has a market capitalization of $95.63 billion, a P/E ratio of -10.63, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a 50 day moving average of $52.05 and a 200-day moving average of $55.77. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same period last year, the business earned ($4.40) EPS. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.28%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Insider Activity

In related news, EVP Samit Hirawat acquired 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.07% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.